Neutralizing antibody Seroconversion (SC) rate response;Specific Th1 cell-mediated immunity (CMI) response;Specific Th1 cell-mediated immunity (CMI) response;Neutralizing antibody Geometric mean fold rise (GMFR) response;Neutralizing antibody Geometric mean fold rise (GMFR) response;Neutralizing antibody Seroconversion (SC) rate response;Neutralizing antibody Geometric mean titers (GMT) response;Neutralizing antibody Geometric mean titers (GMT) response;Serious adverse events (SAEs), Medically attended adverse event (MAAE), adverse events (AEs) leading to withdrawal, adverse event of special interest (AESI) (including vaccine-enhanced disease) and deaths;Percentage of subjects with normal and abnormal clinically significant biochemical values;Number of subjects with normal and abnormal clinically significant biochemical values;Percentage of subjects with normal and abnormal clinically significant haematological values;Number of subjects with normal and abnormal clinically significant haematological values;Percentage of subjects with normal and abnormal clinically significant urine values;Number of subjects with normal and abnormal clinically significant urine values;Unsolicited adverse events (AEs);Solicited local and systemic adverse events (AEs);Immediate adverse event (AEs)

Neutralizing antibody Seroconversion (SC) rate response;Specific Th1 cell-mediated immunity (CMI) response;Specific Th1 cell-mediated immunity (CMI) response;Neutralizing antibody Geometric mean fold rise (GMFR) response;Neutralizing antibody Geometric mean fold rise (GMFR) response;Neutralizing antibody Seroconversion (SC) rate response;Neutralizing antibody Geometric mean titers (GMT) response;Neutralizing antibody Geometric mean titers (GMT) response;Serious adverse events (SAEs), Medically attended adverse event (MAAE), adverse events (AEs) leading to withdrawal, adverse event of special interest (AESI) (including vaccine-enhanced disease) and deaths;Percentage of subjects with normal and abnormal clinically significant biochemical values;Number of subjects with normal and abnormal clinically significant biochemical values;Percentage of subjects with normal and abnormal clinically significant haematological values;Number of subjects with normal and abnormal clinically significant haematological values;Percentage of subjects with normal and abnormal clinically significant urine values;Number of subjects with normal and abnormal clinically significant urine values;Unsolicited adverse events (AEs);Solicited local and systemic adverse events (AEs);Immediate adverse event (AEs)